{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:57:16Z","timestamp":1790675836178,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,2,16]],"date-time":"2020-02-16T00:00:00Z","timestamp":1581811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,16]],"date-time":"2020-02-16T00:00:00Z","timestamp":1581811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Radioligand therapy with [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-617 is efficacious for the treatment of patients with metastasized castration-resistant prostate cancer (mCRPC). Various studies have evaluated the efficacy and safety of [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-617 using a dose of 6.0\u00a0GBq and an 8-week therapy interval. However, the first prospective phase III trial (VISION) plans to use an elevated cumulative dose by applying 7.5\u00a0GBq in a 6-week interval. The aim of the present study was to compare safety and efficacy of the two aforementioned [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-617 therapy regimes (7.5\u00a0GBq every 6\u00a0weeks vs. 6.0\u00a0GBq every 8\u00a0weeks).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A total number of 78 consecutive patients with mCRPC and a history of first-line chemotherapy were included in this retrospective analysis. The outcome of patients treated with 6.0\u00a0GBq [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-617 per cycle (<jats:italic>n<\/jats:italic>\u2009=\u200937) were compared with those treated with 7.5\u00a0GBq (<jats:italic>n<\/jats:italic>\u2009=\u200941) per cycle. The median therapy intervals were 8.4\u00a0weeks (6.0\u00a0GBq group) vs. 6.5 (7.5\u00a0GBq group). PSA response, PSA progression-free survival (PSA-PFS), overall survival, and adverse events were evaluated and compared between both groups. Chi-squared test, Kaplan Meier estimates, Cox regression, and log-rank test were used. The highest decline from pretherapeutic PSA levels was measured as percentage (best PSA response) and compared between groups by Wilcoxon test.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>There was no significant difference comparing the rate of &gt;\u200950% PSA decline or best PSA response between the 6.0\u00a0GBq and 7.5\u00a0GBq group (35% vs. 54%, <jats:italic>p<\/jats:italic>\u2009=\u20090.065; and \u2212\u200940.2% vs. \u2212\u200957.8%, <jats:italic>p<\/jats:italic>\u2009=\u20090.329). The median estimated survival and PSA-PFS did not significantly differ between the 6.0\u00a0GBq and 7.5\u00a0GBq groups as well (11.3 vs. 12.7\u00a0months, <jats:italic>p<\/jats:italic>\u2009=\u20090.384; and 9.5 vs. 12.3\u00a0months, <jats:italic>p<\/jats:italic>\u2009=\u20090.258). There was no significant difference regarding the change of kidney, liver, and blood cell parameters under therapy between the treatment groups.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Higher cumulated doses of [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-617 were well tolerated and caused no significantly increased rate of adverse reactions. Moreover, 7.5\u00a0GBq of [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-617 every 6\u00a0weeks causes slightly higher, though not statistically significant, response rates and seems therefore to be the preferable treatment regime. However, future studies are needed to elucidate the dose-related efficacy of [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-617 as a way to personalized medicine.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00259-020-04703-3","type":"journal-article","created":{"date-parts":[[2020,2,16]],"date-time":"2020-02-16T00:02:52Z","timestamp":1581811372000},"page":"2106-2112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis"],"prefix":"10.1007","volume":"47","author":[{"given":"Robert","family":"Seifert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Schlack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Weckesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"B\u00f6gemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4591-4055","authenticated-orcid":false,"given":"Kambiz","family":"Rahbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,16]]},"reference":[{"key":"4703_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Sch\u00e4fers M, Essler M, et al. German multicenter study investigating 177 Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85\u201390.","journal-title":"J Nucl Med"},{"key":"4703_CR2","doi-asserted-by":"publisher","first-page":"4841","DOI":"10.7150\/thno.35759","volume":"9","author":"K Kessel","year":"2019","unstructured":"Kessel K, Seifert R, Sch\u00e4fers M, Weckesser M, Schlack K, Boegemann M, et al. Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177 Lu-PSMA-617. Theranostics. 2019;9:4841\u20138.","journal-title":"Theranostics."},{"key":"4703_CR3","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s00259-017-3751-z","volume":"44","author":"A Br\u00e4uer","year":"2017","unstructured":"Br\u00e4uer A, Grubert LS, Roll W, Schrader AJ, Sch\u00e4fers M, B\u00f6gemann M, et al. 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1663\u201370.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4703_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00259-014-2978-1","volume":"42","author":"C Kratochwil","year":"2015","unstructured":"Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benesova M, Mier W, et al. [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:987\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4703_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00259-017-3877-z","volume":"45","author":"K Rahbar","year":"2018","unstructured":"Rahbar K, B\u00f6geman M, Yordanova A, Eveslage M, Sch\u00e4fers M, Essler M, et al. Delayed response after repeated177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:243\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4703_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00259-017-3848-4","volume":"45","author":"K Rahbar","year":"2018","unstructured":"Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schafers M, Essler M, et al. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and\/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging. Germany. 2018;45:12\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4703_CR7","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Ping Thang S, Akhurst T, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. Elsevier Ltd. 2018;19:825\u201333.","journal-title":"Lancet Oncol"},{"key":"4703_CR8","doi-asserted-by":"publisher","unstructured":"Rahbar K, Bodei L, Morris MJ. Is the \u201cVISION\u201d of radioligand therapy for prostate cancer becoming reality? An overview of the phase III trial and the importance for the future of theranostics. J Nucl Med. 2019. https:\/\/doi.org\/10.2967\/jnumed.119.234054.","DOI":"10.2967\/jnumed.119.234054"},{"key":"4703_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335.","journal-title":"N Engl J Med"},{"key":"4703_CR10","doi-asserted-by":"publisher","unstructured":"Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP. Clinical outcomes of 177 Lu-PSMA radioligand therapy in taxane chemotherapy pretreated and taxane chemotherapy na\u00efve patients with metastatic castration resistant prostate cancer. J Nucl Med. 2019. https:\/\/doi.org\/10.2967\/jnumed.118.216820.","DOI":"10.2967\/jnumed.118.216820"},{"key":"4703_CR11","doi-asserted-by":"publisher","first-page":"153601211877606","DOI":"10.1177\/1536012118776068","volume":"17","author":"K Rahbar","year":"2018","unstructured":"Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H. PSMA theranostics: current status and future directions. Mol Imaging. 2018;17:153601211877606.","journal-title":"Mol Imaging"},{"key":"4703_CR12","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/RLU.0000000000001240","volume":"41","author":"K Rahbar","year":"2016","unstructured":"Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, et al. Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med. 2016;41:522\u20138.","journal-title":"Clin Nucl Med"},{"key":"4703_CR13","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148\u201359.","journal-title":"J Clin Oncol"},{"key":"4703_CR14","first-page":"114","volume":"5","author":"H Ahmadzadehfar","year":"2015","unstructured":"Ahmadzadehfar H, Rahbar K, K\u00fcrpig S, B\u00f6gemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5:114.","journal-title":"EJNMMI Res"},{"key":"4703_CR15","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00259-014-2713-y","volume":"41","author":"CM Zechmann","year":"2014","unstructured":"Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a 124I\/ 131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280\u201392.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4703_CR16","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Giesel FL, Stefanova M, Bene\u0161ov\u00e1 M, Bronzel M, Afshar-Oromieh A, et al. PSMA-Targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57:1170\u20136.","journal-title":"J Nucl Med"},{"key":"4703_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","volume":"43","author":"A Delker","year":"2015","unstructured":"Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;43:42\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4703_CR18","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.18632\/oncotarget.12240","volume":"8","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Reinhardt S, Ilhan H, Delker A, B\u00f6ning G, Gildehaus FJ, et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2017;8:3581\u201390.","journal-title":"Oncotarget."},{"key":"4703_CR19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2967\/jnumed.117.194209","volume":"59","author":"H Rathke","year":"2018","unstructured":"Rathke H, Giesel FL, Flechsig P, Kopka K, Mier W, Hohenfellner M, et al. Repeated 177Lu-labeled PSMA-617 radioligand therapy using treatment activities of up to 9.3 GBq. J Nucl Med. 2018;59:459\u201365.","journal-title":"J Nucl Med"},{"key":"4703_CR20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.2967\/jnumed.116.178228","volume":"58","author":"J Ferdinandus","year":"2017","unstructured":"Ferdinandus J, Eppard E, Gaertner FC, K\u00fcrpig S, Fimmers R, Yordanova A, et al. Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177 Lu-PSMA-617. J Nucl Med. 2017;58:312\u20139.","journal-title":"J Nucl Med"},{"key":"4703_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373\u20137.","journal-title":"Nature."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04703-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-020-04703-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04703-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T01:27:40Z","timestamp":1613611660000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-020-04703-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,16]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["4703"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-04703-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,16]]},"assertion":[{"value":"21 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no financial or non-financial competing interests according to the subject and matter of the presented article. The University of Muenster received consulting fees from ABX advanced biochemical compounds, Radeberg, Germany, for KR and M.B. Additionally, KR is a clinical consultant for ABX and has received consultant fees from Bayer and lectureship fees from Janssen Cilag, Amgen, AAA, and SIRTEX.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. This study was approved by the local ethics committee (No. 2016-585-f-S, Ethikkommission der \u00c4rztekammer Westfalen-Lippe und der Westf\u00e4lischen Wilhelms-Universit\u00e4t M\u00fcnster).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}